SG11201909478UA - Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication - Google Patents

Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication

Info

Publication number
SG11201909478UA
SG11201909478UA SG11201909478UA SG11201909478UA SG 11201909478U A SG11201909478U A SG 11201909478UA SG 11201909478U A SG11201909478U A SG 11201909478UA SG 11201909478U A SG11201909478U A SG 11201909478UA
Authority
SG
Singapore
Prior art keywords
international
patient
pharmaceutically acceptable
biological sample
pct
Prior art date
Application number
Other languages
English (en)
Inventor
Irina Jacobson
Michael Feese
Sam Lee
Original Assignee
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocrystal Pharma Inc filed Critical Cocrystal Pharma Inc
Publication of SG11201909478UA publication Critical patent/SG11201909478UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201909478U 2017-04-24 2018-04-24 Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication SG11201909478UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762489167P 2017-04-24 2017-04-24
PCT/US2018/028986 WO2018200425A1 (en) 2017-04-24 2018-04-24 Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication

Publications (1)

Publication Number Publication Date
SG11201909478UA true SG11201909478UA (en) 2019-11-28

Family

ID=62117141

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909478U SG11201909478UA (en) 2017-04-24 2018-04-24 Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication

Country Status (19)

Country Link
US (1) US11014941B2 (pt)
EP (1) EP3615545B1 (pt)
JP (1) JP7165721B2 (pt)
KR (1) KR102598466B1 (pt)
CN (1) CN110637022B (pt)
AU (1) AU2018257778B2 (pt)
BR (1) BR112019022307A2 (pt)
CA (1) CA3059449A1 (pt)
DK (1) DK3615545T3 (pt)
EA (1) EA039181B1 (pt)
ES (1) ES2901875T3 (pt)
IL (1) IL269900B (pt)
MX (1) MX2019012759A (pt)
NZ (1) NZ757442A (pt)
PH (1) PH12019502376A1 (pt)
PL (1) PL3615545T3 (pt)
SG (1) SG11201909478UA (pt)
TW (1) TWI778052B (pt)
WO (1) WO2018200425A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004215A (es) * 2018-10-17 2021-07-15 Cocrystal Pharma Inc Combinaciones de inhibidores de la replicación del virus de la gripe.
BR112021009254A2 (pt) * 2018-11-13 2021-08-10 Cocrystal Pharma, Inc. formulações para produtos terapêuticos para influenza
CN113748103A (zh) * 2019-04-26 2021-12-03 日产化学株式会社 芳基磺酸酯化合物的制造方法
EP4180434A1 (en) * 2020-07-10 2023-05-17 Sichuan Haisco Pharmaceutical Co., Ltd. Pb2 inhibitor, and preparation method therefor and use thereof
WO2022109495A1 (en) * 2020-11-23 2022-05-27 The Regents Of The University Of California Methods and compositions for linking rna stem loops

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB278965A (en) 1927-03-24 1927-10-20 Gerhard Haar Improved agricultural plough
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
NO160330C (no) 1982-10-08 1989-04-12 Glaxo Group Ltd Anordning for aa administrere medikamenter til pasienter og medikamentpakning for anordningen.
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4753788A (en) 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
NO166268C (no) 1985-07-30 1991-07-03 Glaxo Group Ltd Innretning for administrering av medikamenter til pasienter.
US4946931A (en) 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
AU6909091A (en) 1989-12-05 1991-06-26 Ramsey Foundation Neurologic agents for nasal administration to the brain
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
JP4859317B2 (ja) 1999-08-06 2012-01-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 薬剤放出生分解性繊維インプラント
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
WO2002013897A2 (en) 2000-08-14 2002-02-21 Advanced Inhalation Research, Inc. Inhalation device and method
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
MXPA04001361A (es) 2001-08-14 2004-05-27 Toyama Chemical Co Ltd Metodo novedoso para inhibir el crecimiento de virus y/o metodo virucida, y un analogo novedoso de un nucleotido de pirazina o de un nucleosido de pirazina.
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
ES2415654T3 (es) 2001-11-20 2013-07-26 Civitas Therapeutics, Inc. Composiciones particuladas mejoradas para suministro pulmonar
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
JP5144070B2 (ja) 2003-09-05 2013-02-13 カーブ テクノロジー，インコーポレイティド 鼻腔深部及び副鼻腔に薬剤を点鼻送達するための一体型ネブライザ及び粒子分散チャンバ
EP2332940B1 (en) 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
RU2453548C2 (ru) 2006-01-17 2012-06-20 Вертекс Фармасьютикалз Инкорпорейтед Азаиндолы, полезные в качестве ингибиторов янус-киназ
ES2604667T3 (es) * 2009-06-17 2017-03-08 Vertex Pharmaceuticals Incorporated Inhibidores de la replicación de virus de influenza
JP6242378B2 (ja) 2012-03-13 2017-12-06 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス処置のための２’−置換カルバヌクレオシド類似体
MX2016006200A (es) 2013-11-13 2016-08-08 Vertex Pharma Metodos para preparar inhibidores de la replicacion de virus de influenza.
HUE053595T2 (hu) 2014-09-08 2021-07-28 Janssen Sciences Ireland Unlimited Co Pirrolopirimidinek influenzavírus-fertõzésnél történõ alkalmazásra
CN105524067A (zh) 2014-09-28 2016-04-27 江苏柯菲平医药股份有限公司 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
FR3039227B1 (fr) 2015-07-22 2019-12-27 Safran Aircraft Engines Aeronef comprenant un propulseur arriere carene avec stator d’entree a volets mobiles
JP6952695B2 (ja) * 2015-12-09 2021-10-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． インフルエンザウイルス複製の阻害剤、その適用方法および使用
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza
WO2017133667A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017198122A1 (zh) * 2016-05-19 2017-11-23 四川大学 抗流感小分子化合物及其制备方法和用途
DE102017000989A1 (de) * 2017-02-03 2018-08-09 Evonik Degussa Gmbh Verfahren zur Herstellung von Cyclododecanon

Also Published As

Publication number Publication date
JP2020517738A (ja) 2020-06-18
EP3615545B1 (en) 2021-09-01
DK3615545T3 (da) 2021-11-22
BR112019022307A2 (pt) 2020-05-26
EP3615545A1 (en) 2020-03-04
JP7165721B2 (ja) 2022-11-04
IL269900B (en) 2022-05-01
CN110637022A (zh) 2019-12-31
AU2018257778B2 (en) 2022-02-17
EA201992543A1 (ru) 2020-03-24
PL3615545T3 (pl) 2022-01-10
US11014941B2 (en) 2021-05-25
AU2018257778A1 (en) 2019-10-10
CA3059449A1 (en) 2018-11-01
EA039181B1 (ru) 2021-12-15
NZ757442A (en) 2022-10-28
PH12019502376A1 (en) 2020-09-14
KR102598466B1 (ko) 2023-11-03
CN110637022B (zh) 2022-09-16
TWI778052B (zh) 2022-09-21
ES2901875T3 (es) 2022-03-24
US20200123177A1 (en) 2020-04-23
MX2019012759A (es) 2019-12-16
TW201839003A (zh) 2018-11-01
WO2018200425A1 (en) 2018-11-01
KR20190140971A (ko) 2019-12-20

Similar Documents

Publication Publication Date Title
SG11201909478UA (en) Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
SG11202000325UA (en) Selective inhibitors of nlrp3 inflammasome
SG11201909325RA (en) 2-amino-quinoline derivatives
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201808003RA (en) Bromodomain inhibitors
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201809559UA (en) Substituted pyridines as inhibitors of dnmt1
SG11201805645QA (en) Lsd1 inhibitors
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201908351TA (en) Indole derivatives as efflux pump inhibitors
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201908788YA (en) Combinations of chk1- and wee1 - inhibitors
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806480UA (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201906164RA (en) Bicyclic inhibitors of histone deacetylase
SG11201902988UA (en) Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof
SG11201901576QA (en) Dosage regimen for a controlled-release pth compound
SG11201908568XA (en) Therapeutic compounds and methods
SG11201908660RA (en) N-substituted indole derivatives
SG11201407337QA (en) Cyclodextrin complexation methods for formulating peptide proteasome inhibitors